2016 Fiscal Year Final Research Report
Drug discovery based on novel concept for overcoming high-risk myeloma which is still intractable despite of recent progress in the treatment
| Project/Area Number |
26461432
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
Hattori Yutaka 慶應義塾大学, 薬学部(芝共立), 教授 (20189575)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 内科 / 薬学 |
|---|
| Outline of Final Research Achievements |
Despite of the use of newly developed drugs, multiple myeloma (MM) with high-risk cytogenetic changes revealed significantly poor prognosis. Most patients acquired drug resistance and developed extra-medullary diseases.We found that N-cadherin and other mesenchymal genes were highly expressed in t(4;14)-positive high-risk MM patients, and E-cadherin and other epithelial genes were expressed in MM patients with normal karyotype. Those cadherin-positive MM cells demonstrated tumorigenicity to SCID mice.We also developed a new immunomudulatory drug (IMiDs), TC11, which showed anti-tumor activity via cereblon-independent pathway unlike previously developed IMiDs.In addition, we tried structural modification of TC11 and succeeded in significantly increasing water-solublity of TC11.
|
| Free Research Field |
血液内科学
|
